Principal Financial Group Inc. Acquires 31,574 Shares of Option Care Health, Inc. $OPCH

Principal Financial Group Inc. boosted its holdings in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 6.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 508,426 shares of the company’s stock after purchasing an additional 31,574 shares during the quarter. Principal Financial Group Inc. owned about 0.32% of Option Care Health worth $13,687,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its position in shares of Option Care Health by 20.7% in the first quarter. Royal Bank of Canada now owns 231,161 shares of the company’s stock valued at $8,078,000 after acquiring an additional 39,661 shares during the period. AQR Capital Management LLC increased its position in Option Care Health by 162.6% during the first quarter. AQR Capital Management LLC now owns 41,633 shares of the company’s stock worth $1,450,000 after acquiring an additional 25,777 shares during the period. Empowered Funds LLC bought a new position in Option Care Health during the first quarter worth $208,000. Invesco Ltd. raised its stake in Option Care Health by 2.7% during the 2nd quarter. Invesco Ltd. now owns 294,363 shares of the company’s stock valued at $9,561,000 after purchasing an additional 7,678 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its stake in Option Care Health by 528.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,407 shares of the company’s stock valued at $46,000 after purchasing an additional 1,183 shares during the last quarter. Institutional investors and hedge funds own 98.05% of the company’s stock.

Option Care Health Stock Performance

OPCH opened at $21.08 on Friday. The company has a market capitalization of $3.31 billion, a price-to-earnings ratio of 16.34, a P/E/G ratio of 1.18 and a beta of 0.65. The business’s 50-day moving average price is $21.28 and its two-hundred day moving average price is $27.16. Option Care Health, Inc. has a 1 year low of $18.01 and a 1 year high of $36.80. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.64 and a quick ratio of 1.07.

Option Care Health (NASDAQ:OPCH) last posted its quarterly earnings data on Thursday, April 30th. The company reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.03. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.39 billion. Option Care Health had a return on equity of 18.17% and a net margin of 3.64%.Option Care Health’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.40 earnings per share. Option Care Health has set its FY 2026 guidance at 1.820-1.920 EPS. Equities analysts expect that Option Care Health, Inc. will post 1.64 EPS for the current fiscal year.

Insiders Place Their Bets

In other Option Care Health news, Director Harry M. Jansen Kraemer, Jr. purchased 36,610 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was bought at an average cost of $21.41 per share, with a total value of $783,820.10. Following the purchase, the director directly owned 450,000 shares of the company’s stock, valued at $9,634,500. The trade was a 8.86% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Timothy P. Sullivan acquired 24,154 shares of the stock in a transaction dated Thursday, May 7th. The stock was acquired at an average price of $20.69 per share, for a total transaction of $499,746.26. Following the completion of the acquisition, the director directly owned 73,383 shares of the company’s stock, valued at $1,518,294.27. The trade was a 49.06% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 73,264 shares of company stock valued at $1,548,316 in the last quarter. 1.70% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. TD Cowen reduced their price target on shares of Option Care Health from $37.00 to $23.00 and set a “hold” rating for the company in a report on Friday, May 1st. Barrington Research cut their price objective on shares of Option Care Health from $42.00 to $32.00 and set an “outperform” rating for the company in a research report on Friday, May 1st. Weiss Ratings cut shares of Option Care Health from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 11th. Truist Financial set a $30.00 target price on Option Care Health in a research report on Friday, May 1st. Finally, Bank of America lowered Option Care Health from a “buy” rating to a “neutral” rating and set a $22.00 price target on the stock. in a research note on Friday, May 1st. Eight analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, Option Care Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.08.

Option Care Health Profile

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.